TABLE 1.

Pharmacokinetic parameters for saquinavir and ritonavir^a

Study drug	Group	Sampling day	nb	Pharmacokinetic parameterc (mean ± SD)
				Tmax (h)	Cmax (ng/ml)	Cmin (ng/ml)	AUC0-12 (ng·h/ml)
Saquinavir	1	14	19	3.6 ± 1.1	1,264 ± 837	322 ± 316	8,819 ± 6,899
	1	36	19	4.2 ± 0.5	1,144 ± 726	274 ± 189	7,725 ± 4,878
	2	43	11	4.2 ± 0.8	2,057 ± 970	534 ± 425	13,321 ± 7,180
	3	42	9	4.3 ± 0.5	4,872 ± 1,910	841 ± 417	31,169 ± 13,762
Ritonavir	1	14	19	3.7 ± 1.1	1,683 ± 595	292 ± 131	9,939 ± 3,844
	1	36	19	4.3 ± 0.7	1,688 ± 455	293 ± 94	9,830 ± 2,505
	2	43	11	4.2 ± 0.8	2,479 ± 538	500 ± 102	15,239 ± 3,088
	3	42	9	3.9 ± 1.1	1,724 ± 388	265 ± 132	10,119 ± 3,003

^aThe sanpling days and drug treatments of groups were as follows: day 14, saquinavir-ritonavir (1,000 mg of saquinavir and 100 mg of ritonavir [1,000/100 mg]) twice daily (BID); day 36, saquinavir-ritonavir (1,000/100 mg) BID plus rifabutin (150 mg) once daily (QD); day 43, rifabutin (150 mg) once every 3 days (Q3D) plus saquinavir-ritonavir (1,000/100 mg) BID; and day 42, rifabutin (150 mg) once every 4 days (Q4D) plus saquinavir-ritonavir (1,000/100 mg) BID.

^bn is the number of subjects with pharmacokinetic data.

^cAUC_0-12, area under the concentration-time curve from 0 to 12 h; C_max, maximum observed drug concentration in plasma; C_min, minimum observed drug concentration in plasma at the end of the dosing interval; T_max, time to C_max.